Gilead to file new CAR-T, setting up potential mid-2020 launchGilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing Share XGilead to file new CAR-T, setting up potential mid-2020 launchhttps://pharmaphorum.com/news/gilead-to-file-new-car-t/
Understanding the evolving CAR-T marketIn August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor Share XUnderstanding the evolving CAR-T markethttps://pharmaphorum.com/partner-content/understanding-the-evolving-car-t-market/
Q&A: Draper’s Jenna Balestrini on the future of CAR-TAs exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential. Jenna Share XQ&A: Draper’s Jenna Balestrini on the future of CAR-Thttps://pharmaphorum.com/views-analysis-oncology/qa-drapers-jenna-balestrini-on-the-future-of-car-t/
CAR-TCR Summit EuropeEngineering A Cancer-Free World Share XCAR-TCR Summit Europehttps://pharmaphorum.com/events/car-tcr-summit-europe/
Q&A: Sangamo’s Duncan McKay on genomic medicinesWe talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future Share XQ&A: Sangamo’s Duncan McKay on genomic medicineshttps://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
Delivering innovative therapies with close industry-NHS partnershipsIt was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE) Share XDelivering innovative therapies with close industry-NHS partnershipshttps://pharmaphorum.com/r-d/views-analysis-r-d/delivering-innovative-therapies-with-close-industry-nhs-partnerships/
